|
|
|
Senesco
Chooses VGXI To Produce Factor 5A Plasmid
|
| NEW
BRUNSWICK, N.J. – July 3, 2008 – |
|
Senesco Technologies, Inc. ("Senesco"
or the "Company") (AMEX:SNT) announced today that it has contracted
with VGXI, Inc. (The Woodlands, TX) (“VGXI”) to supply the
plasmid portion of the Company’s combination therapy consisting
of the Factor 5A gene and siRNA against Factor 5A.
Senesco has previously reported positive preclinical in vivo results using
its combination siRNA and plasmid against subcutaneous multiple myeloma
tumors in immunodeficient mice. The Factor 5A plasmid being produced by
VGXI, as Senesco’s preclinical data has shown, should cause cancer
cells to enter apoptosis, or programmed cell death.
“VGXI’s manufacturing and technical expertise in producing
plasmids for Senesco’s planned toxicology study and ultimately our
clinical trial led us to choose them. We are pleased to be working with
a company that has such an outstanding reputation in the field”,
commented Bruce Galton, Senesco’s President and CEO.
Henry Hebel, Vice President of Operations for VGXI said, “We believe
that our ability to quickly supply the preclinical and clinical needs
of our clients will allow Senesco to rapidly advance their programs. We
are continuing to expand our collaborative development services to meet
the growing needs for a wide variety of plasmid based products."
Cautionary
Factors That May Affect Future Results - Materials in this
Web site contain information that includes or is based upon forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Forward-looking statements relate to expectations or
forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts.
They use words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning
in connection with a discussion of potential future events, circumstances
or future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of contingencies
such as legal proceedings, and financial results. Any or all of our
forward-looking statements here or in other publications may turn
out to be wrong. They can be affected by inaccurate assumptions or
by known or unknown risks and uncertainties. Many such factors will
be important in determining our actual future results. Consequently,
no forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product availability,
current and future branded and generic competition, federal and state
regulations and legislation, manufacturing issues, timing of the elimination
of trade buying, patent positions, litigations and investigations.
Our actual results may vary materially, and there are no guarantees
about the performance or valuation of VGX stock. It is also important
to read the disclosure notice contained in many of the individual
VGX documents available on this Web site as many contain important
information on such cautionary factors as of the date of the individual
document. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further disclosures
we make on related subjects in our reports. |
About VGXI Inc.
VGXI Inc. is a leading manufacturer of DNA plasmids, and its cGMP and
non-cGMP products have passed rigorous reviews by several international
regulatory agencies. VGXI offers a wide variety of contract manufacturing
services to outside client organizations. The Company’s cGMP manufacturing
facility in The Woodlands, Texas is a flexible, purpose-built facility
used for research, development, and clinical supply. The site includes
500-liter and 100-liter fermentors and incorporates a cost-effective process.
VGX International also has initiated a project to build and operate a
3000-liter scale cGMP, DNA plasmid manufacturing facility in Asia.
Company Contact:
Henry Hebel
Vice President, Manufacturing and Operations
Tel. 281.296.7300
Fax 281.296.7333
E-mail: hhebel@vgxii.com
www.vgxii.com
About Senesco Technologies, Inc.
Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered
in New Brunswick, NJ. Senesco has initiated preclinical research to trigger
or delay cell death in mammals (apoptosis) to determine if the technology
is applicable in human medicine. Accelerating apoptosis may have applications
to development of cancer treatments. Delaying apoptosis may have applications
to certain inflammatory and ischemic diseases. Senesco takes its name
from the scientific term for the aging of plant cells: senescence. Delaying
cell breakdown in plants extends freshness after harvesting, while increasing
crop yields, plant size and resistance to environmental stress. The Company
believes that its technology can be used to develop superior strains of
crops without any modification other than delaying natural plant senescence.
Senesco has partnered with leading-edge companies engaged in agricultural
biotechnology and earns research and development fees for applying its
gene-regulating platform technology to enhance its partners' products.
Certain statements included in this press release are forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Actual results could differ materially from such statements
expressed or implied herein as a result of a variety of factors, including,
but not limited to: the Company’s ability to raise additional capital
to fund its research and development efforts; the development of the Company’s
gene technology; the approval of the Company’s patent applications;
the successful implementation of the Company’s research and development
programs and joint ventures; the success of the Company's license agreements;
the acceptance by the market of the Company’s products; success
of the Company’s preliminary studies and preclinical research; competition
and the timing of projects and trends in future operating performance,
our ability to maintain our continued listing standards for the next 12
months, as well as other factors expressed from time to time in the Company’s
periodic filings with the Securities and Exchange Commission (the "SEC").
As a result, this press release should be read in conjunction with the
Company’s periodic filings with the SEC. The forward-looking statements
contained herein are made only as of the date of this press release, and
the Company undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstances.
|
